Table 2. Immunological Characteristics and Therapy.
Comparison of sensitization status and immunomodulatory treatments between AT1R-Ab positive and negative patients. HLA, human leukocyte antigen; SD, standard deviation; PRA, panel reactive antibody; ATG, anti-thymocyte globulin; IL-2, interleukin-2; DSA, donor specific antibody; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; IQR, interquartile range; IVIG, intravenous immunoglobulin
| AT1R-Ab Positive (n=38) |
AT1R-Ab Negative (n=27) |
p-value | |
|---|---|---|---|
| HLA Mismatch, mean (SD) | 1.2 (0.6) | 1.2 (0.5) | 0.730 |
| Primary Transplant | 33 (86.8%) | 26 (96.3%) | 0.388 |
| Baseline PRA Class I > 20% | 3 (7.9%) | 1 (3.7%) | 0.636 |
| Baseline PRA Class II > 20% | 6 (15.8%) | 1 (3.7%) | 0.224 |
| ATG Induction (vs. IL - 2 Inhibitor) | 6 (15.8%) | 0 (0%) | 0.037 |
| Steroids Based Immunosuppression | 17 (44.7%) | 14 (51.9%) | 0.621 |
| Presence of HLA DSA in the First 2 Years Post-Transplant | >0.99 | ||
| Negative | 27 (71.1%) | 19 (70.4%) | |
| Class I Only | 3 (7.9%) | 2 (7.4%) | |
| Class II Only | 7 (18.4%) | 5 (18.5%) | |
| Class I and Class II | 1 (2.6%) | 1 (3.7%) | |
| ACE Inhibitor Treatment | 10 (26.3%) | 3 (11.1%) | 0.209 |
| ARB Treatment | 1 (2.6%) | 0 (0%) | >0.99 |
| Immunomodulatory Treatment Days, median (IQR) | 6 (0–21.5) | 0 (0–3) | 0.010 |
| Any Immunomodulatory Treatment | 23 (60.5%) | 12 (44.4%) | 0.219 |
|
Immunomodulatory Treatment by Medication
|
|||
| High Dose Steroids | 15 (39.5%) | 8 (29.6%) | 0.444 |
| IVIG | 11 (28.9%) | 4 (14.8%) | 0.239 |
| ATG | 15 (39.5%) | 5 (18.5%) | 0.102 |
| Rituximab | 6 (15.8%) | 1 (3.7%) | 0.224 |
| Plasmapheresis | 11 (28.9%) | 0 (0%) | 0.002 |
| Bortezomib | 2 (5.3%) | 0 (0%) | 0.507 |